MedTech News
.................... by Andrew Celentano
Beckman Coulter Diagnostics Receives U.S. FDA Clearance for Rapid Bacterial vs. Viral Assay Providing Results in as Little as 15 Minutes for Adults and Children
BREA, Calif., Nov. 3, 2026 /PRNewswire/ — Beckman Coulter Diagnostics, a Danaher company and a global leader in clinical diagnostics, today announced U.S. FDA clearance of the Access MeMed BV® assay, a rapid host-response blood test that helps clinicians distinguish bacterial from viral infections in adult and pediatric patients. Available on the DxI 9000 and Access 2 immunoassay analyzers already installed in hospital laboratories nationwide, the new assay provides timely information aiding treatment decisions without requiring new instrumentation or changes to existing testing workflows. On the DxI 9000 Analyzer, results are available in as little as 15 minutes.
‘Gatekeeper’ cells can restrict the immune response to cancer
A new study led by King’s College London has found that chemotherapy helps attract a specific population of immune cells called stem-like T cells toward tumors.
New study identifies biological mechanism driving therapy resistance in advanced prostate cancer
A multi-institutional collaborative study led by researchers at the University of Chicago and the Fred Hutchinson Cancer Center has identified a previously unknown biological mechanism that controls cell identity and treatment resistance in advanced prostate cancer.
Onkos Surgical Continues Expansion of NanoCept® Antibacterial Technology with Latest FDA Clearance
PARSIPPANY, N.J., Nov. 6, 2026 /PRNewswire/ — Onkos Surgical, Inc. today announced a new FDA 510(k) clearance for its NanoCept® Antibacterial Technology, expanding its application to a broader offering of titanium components in the ELEOS™ Limb Salvage System. This marks another milestone in the company’s continued investment in antibacterial innovation.
DNA ‘switch’ uncovers new brake on breast cancer growth
Adelaide University researchers have found a DNA “switch” that helps the body stop the growth of the most common form of breast cancer, providing new insights that could help with future treatments
Two compounds target drug-resistant brain cancer cells in laboratory tests
The current standard of care involves the use of temozolomide (TMZ), a chemotherapy medication. However, the tumor can be difficult to control because cancer cells evolve to evade the effects of such treatments. Thus, finding new ways to target these cells is an important area in cancer research.
AI-powered smartwatch detects high blood pressure with sensitivity similar to office screening
Smartwatches may be able to detect hypertension (high blood pressure) with the help of an artificial intelligence (AI) system that interprets sensor readings, a paper in Nature reports.
Evident Vascular Receives FDA Approval for High-Fidelity AI-Powered IVUS Imaging Platform
Evident Vascular has announced U.S. Food and Drug Administration 510(k) clearance for the Evident Vascular Guidance System and Evident peripheral imaging catheters. The Guidance System is intended for ultrasound examination of intravascular pathology during peripheral vascular interventions.